RxDoctor Payments Data

Riaz Haque, MD

Family Medicine · New Orleans, LANPI 1881697852

Payments from drug & device makers

$4,056in general payments, 2019–2025

Across 231 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$583
  • AbbVie$507
  • Pfizer$424
  • Novo Nordisk$361
  • Abbott$263
  • Lilly USA, LLC$205
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,056 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$157,580
Medicare patients
251
Services billed
3,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$231,367
JardianceEmpagliflozin111$131,315
EliquisApixaban111$92,295
JanuviaSitagliptin Phosphate78$76,867
FarxigaDapagliflozin Propanediol60$68,054
TrulicityDulaglutide39$54,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$39,865
LinzessLinaclotide47$38,878
TradjentaLinagliptin57$38,301
XareltoRivaroxaban34$33,268
Janumet XrSitagliptin Phos/Metformin Hcl21$25,841
MyrbetriqMirabegron32$25,696
GemtesaVibegron11$10,144
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$9,850
Atorvastatin Calcium764$7,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$361$231,367144 claims
Boehringer IngelheimJardiance, Tradjenta$78$169,615168 claims
MerckJanuvia, Janumet Xr$39$102,70899 claims
PfizerEliquis$424$92,295111 claims
AstraZenecaFarxiga$583$68,05460 claims
Lilly USA, LLCTrulicity$205$54,74139 claims
GSKTrelegy Ellipta, Arnuity Ellipta$70$42,75542 claims
AbbVieLinzess$507$38,87847 claims
Johnson & JohnsonXarelto$79$33,26834 claims
Astellas Pharma US IncMyrbetriq$182$25,69632 claims
Indivior Inc.Suboxone$21$3,82315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →